Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.49 |
| ▸ | VDR | P11473 | 4/20 | 0.44 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165775 | 1.00 | CYP24A1 (0.49) | CYP24A1VDRCYP27B1 | |
| SCHEMBL2164599 | 1.00 | CYP24A1 (0.49) | CYP24A1VDRCYP27B1 | |
| SCHEMBL20243718 | 1.00 | CYP24A1 (0.49) | CYP24A1VDRCYP27B1 | |
| SCHEMBL20243225 | 0.92 | CYP24A1 (0.49) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7162545 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7162548 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7165878 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7161812 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7161814 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 | |
| SCHEMBL7166656 | 0.88 | CYP24A1 (0.45) | CYP24A1VDRCYP27B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985744-B2 | Administering 9,10-secopregna-5,7,10(19),16- tetraene derivative to a patient for treating skin diseases such as psoriasis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20040019023-A1 | Vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1295871-A1 | VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019023-A1 | Vitamin d derivatives | VDR, CYP24A1, CYP2R1 | CYP24A1 2/4885VDR 1/4885CYP27B1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.